April 20, 2014 5:52 AM ET


Company Overview of Arteriocyte, Inc.

Company Overview

Arteriocyte, Inc., a clinical stage biotechnology company, develops stem cell and tissue engineering based therapies. It offers platelet rich plasma processing, automated cord blood processing, autologous stem cell therapy, allogeneic stem cell therapy, cell delivery and localization, protein co-delivery, cellular expansion, and therapeutic angiogenesis based solutions. The company also provides autologous platelet separator systems, sterile disposables, demineralized bone matrix powder, and demineralized bone matrix gel; and hematopoietic stem cell expansion kits for research applications. In addition, it develops cell therapy and tissue engineering technologies for cardiovascular, orthoped...

7100 Euclid Avenue

Suite 270

Cleveland, OH 44103

United States

Founded in 2004





Key Executives for Arteriocyte, Inc.

Chief Executive Officer
Co-Founder and Chief Medical Officer
Chief Financial Officer and Chief Operating Officer
Vice President and General Manager of Research & Development
Vice President of Clinical and Regulatory Affairs
Compensation as of Fiscal Year 2013.

Arteriocyte, Inc. Key Developments

Arteriocyte, Inc. Wins BARDA Contract Valued up to $101.1 Million for Advanced Development of Arteriocyte's Magellan(R) BioBandageTM for Thermal Radiation Injury

Arteriocyte, Inc. announced that it has been awarded a contract valued at up to $101.1 million (if all contract options are exercised), by the U.S. Department of Health and Human Services. The Biomedical Advanced Research and Development Authority (BARDA) awarded this contract. The contract supports research and development of the Magellan(R) Bio-Bandage(TM) and clinical evaluation to improve the existing standard of care in definitive burn treatments. The award consists of a two-year base contract totaling $11.8 million. If milestones are met, then at BARDA's discretion, additional options may be exercised to support advanced development over the next three years. The total award will support preclinical, clinical, regulatory and additional device modifications to Arteriocyte's existing Magellan(R) technology in order to complete additional FDA approvals for the use of Magellan(R) Bio-Bandage(TM) to treat thermal burn injury.

Arteriocyte Announces Launch of Compass Biomedical

Arteriocyte, Inc. announced the launch of Compass Biomedical, the commercial tools division of Arteriocyte that supplies novel cell culturing products and technologies for translational research. As part of the Arteriocyte family, Compass Biomedical has access to the pipeline of cutting edge research from Arteriocyte's research and development team, as well as collaboration partnerships with leading research institutions making Compass Biomedical an ideal choice to help accelerate the transition from basic research to clinical application. Compass Biomedical already supplies 3 product lines: 1) NANEX(TM) Cell Culture and Expansion Kit; 2) Adhere-34(TM) Cell Culture and Expansion Bag; and 3) PLUS(TM) Cell Culture Supplement. Compass Biomedical's core products are based upon the NANEX(TM) biofunctional nanofiber-based technology, that was designed to partially mimic key features of human bone marrow enabling rapid ex vivo cell growth and expansion while maintaining the stem cell's properties. It is an ideal solution for rapidly culturing hematopoietic stem and progenitor cells (HSC/HPCs) for basic research, therapeutics, drug discovery, and screening. These expanded cells have been used to grow new blood cells (including red blood cells and platelets) and new blood vessels. One of the major challenges in cellular therapy research is the limited number of stem cells present in adult human tissues, which today limits the research and clinical applications of stem cell technology. The NANEX(TM) Cell Culture and Expansion Kit has been designed specifically for the ex vivo expansion of human bone marrow, peripheral blood, and umbilical cord blood derived HSCs/HPCs. Adhere-34(TM) incorporates the NANEX(TM) nanofiber technology into a fully closed system, enabling sterile and convenient stem cell culturing and rapid expansion for a variety of applications. Adhere-34(TM) will enable researchers to seamlessly transition from the Research Use Only NANEX(TM) Cell Culture and Expansion Kit (in multi-well plate form) to the closed culture ADHERE-34(TM) system, which was developed specifically for use in clinical protocols. PLUS(TM) Cell Culture Supplement is a cytokine rich replacement for fetal bovine serum (FBS). PLUS(TM) is derived from human platelet lysate and is made using state of the art manufacturing techniques. PLUS(TM) provides a safe, xeno-free serology tested product that minimizes sample variation. PLUS(TM) Cell Culture Supplement has been shown to enhance growth rates of mesenchymal stem cells (MSC) while maintaining key MSC phenotypes when compared to fetal bovine serum.

Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors

Arteriocyte announced approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan(R) System technology in the treatment of thermal burn wounds. The FDA Investigational Device Exemption (IDE-15140) allows Arteriocyte and its clinical partners to initiate evaluation of autologous platelet gel (APG) (using the Magellan(R) Autologous Platelet Separator technology) as an adjunctive therapy for autologous skin grafting in patients with thermal injuries. This treatment has been developed in partnership with the United States Telemedicine and Advanced Technology Research Center (TATRC), and the University of Utah Health Science Center and Intermountain Burn Center. Arteriocyte is initiating a series of investigations employing Arteriocyte's Magellan(R) Autologous Platelet Rich Plasma and Bone Marrow Derived Stem Cell Based Therapies for Burn Wounds as part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program. The Magellan(R) System is an FDA 510(k) cleared medical device for the rapid production of Platelet Rich Plasma from blood and bone marrow that can be applied to a surgical site as surgeons deem necessary for their clinical use requirements. The current clinical protocol will evaluate the Magellan(R) Autologous Platelet Gel as an adjunctive therapy to improving skin graft acceptance and integration in thermally injured patients. Autologous Platelet Gel is used to improve adherence of the autologous skin graft, while providing beneficial growth factors and antimicrobial protection ensuring graft survival.

Similar Private Companies By Industry

Company Name Region
Abiomed R&D, Inc. United States
Ala Wai Pharma, Inc. United States
Alkermes Inc. United States
Ras Therapeutics, Inc. United States
Immpheron Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Arteriocyte, Inc., please visit arteriocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.